A PHASE 4, MULTICENTRE, OPEN-LABEL STUDY OF INTRAVENOUS BELIMUMAB IN PAEDIATRIC PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS IN CHINA

被引：0

作者：

Li, C. ^{[1
]}

Zhang, J. ^{[1
]}

Yu, H. ^{[2
]}

Li, Z. ^{[3
]}

Yang, S. ^{[4
]}

Lu, M. ^{[5
]}

Feng, Q. ^{[6
]}

Li, X. ^{[7
]}

Sun, L. ^{[8
]}

Tang, X. ^{[9
]}

Chen, J. ^{[10
]}

Wang, C. ^{[10
]}

Assudani, D. ^{[11
]}

机构：

[1] Capital Med Univ, Beijing Childrens Hosp, Rheumatol & Immunol Dept, Beijing, Peoples R China

[2] Nanjing Med Univ, Childrens Hosp, Rheumatol & Immunol Dept, Nanjing, Peoples R China

[3] Hunan Childrens Hosp, Rheumatol & Immunol Dept, Nephropathy, Changsha, Peoples R China

[4] First Hosp Jilin Univ, Pediat Rheumatol Immunol Dept, Changchun, Peoples R China

[5] Zhejiang Univ, Childrens Hosp, Coll Med, Rheumatol & Immunol Dept, Hangzhou, Peoples R China

[6] Soochow Univ, Childrens Hosp, Rheumatol & Immunol Dept, Suzhou, Peoples R China

[7] Xian Children Hosp, Rheumatol & Immunol Dept, Xian, Peoples R China

[8] Fudan Univ, Childrens Hosp, Rheumatol Dept, Shanghai, Peoples R China

[9] Chongqing Med Univ, Childrens Hosp, Rheumatol & Immunol Dept, Chongqing, Peoples R China

[10] GSK, Res & Dev, Shanghai, Peoples R China

[11] GSK, Clin Sci, Immunol, Brentford, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2025年 / 84卷

关键词：

biological DMARD; Glucocorticoids; Safety; Clinical Trial;

D O I：

10.1136/annrheumdis-2025-eular.B941

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

ABS1153

引用

页数：2

共 4 条

[1] Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial [J].

Brunner, Hermine, I ;

Abud-Mendoza, Carlos ;

Viola, Diego O. ;

Calvo Penades, Inmaculada ;

Levy, Deborah ;

Anton, Jordi ;

Calderon, Julia E. ;

Chasnyk, Vyacheslav G. ;

Ferrandiz, Manuel A. ;

Keltsev, Vladimir ;

Paz Gastanaga, Maria E. ;

Shishov, Michael ;

Boteanu, Alina Lucica ;

Henrickson, Michael ;

Bass, Damon ;

Clark, Kenneth ;

Hammer, Anne ;

Ji, Beulah N. ;

Nino, Antonio ;

Roth, David A. ;

Struemper, Herbert ;

Wang, Mei-Lun ;

Martini, Alberto ;

Lovell, Daniel ;

Ruperto, Nicolino .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (10) :1340-1348

[2] A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus [J].

Furie, Richard ;

Petri, Michelle ;

Zamani, Omid ;

Cervera, Ricard ;

Wallace, Daniel J. ;

Tegzova, Dana ;

Sanchez-Guerrero, Jorge ;

Schwarting, Andreas ;

Merrill, Joan T. ;

Chatham, W. Winn ;

Stohl, William ;

Ginzler, Ellen M. ;

Hough, Douglas R. ;

Zhong, Z. John ;

Freimuth, William ;

van Vollenhoven, Ronald F. .

ARTHRITIS AND RHEUMATISM, 2011, 63 (12) :3918-3930

[3] Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial [J].

Navarra, Sandra V. ;

Guzman, Renato M. ;

Gallacher, Alberto E. ;

Hall, Stephen ;

Levy, Roger A. ;

Jimenez, Renato E. ;

Li, Edmund K-M ;

Thomas, Mathew ;

Kim, Ho-Youn ;

Leon, Manuel G. ;

Tanasescu, Coman ;

Nasonov, Eugeny ;

Lan, Joung-Liang ;

Pineda, Lilia ;

Zhong, Z. John ;

Freimuth, William ;

Petri, Michelle A. .

LANCET, 2011, 377 (9767) :721-731

[4] A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea [J].

Zhang, Fengchun ;

Bae, Sang-Cheol ;

Bass, Damon ;

Chu, Myron ;

Egginton, Sally ;

Gordon, David ;

Roth, David A. ;

Zheng, Jie ;

Tanaka, Yoshiya .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (03) :355-363

← 1 →